Loading
PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP. Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signalling pathway.
Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.53, somatic mutation 0.23, clinical 0.96).
In plain words · PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP.
No product in this corpus aims at PDE3A yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PDE3A: RNA tissue enhanced (blood vessel 20 nTPM, heart muscle 28 nTPM); high antibody staining in 1 normal tissue; highest cancer staining prostate cancer (10 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (essential thrombocythemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PDE3A tissue; Open Targets ENSG00000172572 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Meacci et al, Proc. Natl. Acad. Sci. U.S.A, 1992, "Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase". Source.
Sources: HGNC HGNC:8778 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14432 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000172572 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: myeloproliferative neoplasm 0.59, essential thrombocythemia 0.58 (GraphQL API, CC0))
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP. Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signalling pathway. E2 stabilises the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling. Location: Membrane; Cytoplasm, cytosol (UniProt). Locus 12p12.2 (HGNC).
RNA: tissue enhanced (blood vessel 20 nTPM, heart muscle 28 nTPM), detected in many normal tissues.
Medium: Appendix, Bronchus, Colon, Duodenum, Endometrium, Epididymis, Fallopian tube, Gallbladder.
Medium only: breast cancer, carcinoid, endometrial cancer, liver cancer.
HPA PDE3A tissue · HPA PDE3A pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PDE3A" OR ABSTRACT:"PDE3A" OR TITLE:"phosphodiesterase 3A" OR ABSTRACT:"phosphodiesterase 3A" OR TITLE:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A" OR ABSTRACT:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A" OR TITLE:"CGI-PDE" OR ABSTRACT:"CGI-PDE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDE3A, not a curated reading list.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.